Liposome-containing composition

Abstract

We provide liposome-containing products with excellent stability and usability. [Solution] Prepare a composition containing (A) liposomes; and (B) at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

Description

Technical Field

[0007]

[0001] The present invention relates to a liposome-containing composition.

Background Art

[0002] Liposomes are single or multi-layered closed vesicles of phospholipids and can contain desired components. Liposomes are composed of lipids similar to biological membranes, have the property of easily binding to cell membranes, and have a high affinity for living organisms. For this reason, for example, in pharmaceuticals, they are used as a means for delivering an active ingredient into the living body, or as a means for delivering a water-soluble component that is difficult to penetrate the skin to the stratum corneum.

[0003] Ascorbic acid is known to exhibit various effects such as anti-inflammatory effect, acne improvement effect, whitening effect, anti-aging effect, antioxidant effect, cell activation effect by promoting the synthesis of biological components such as collagen, and effect of suppressing cell damage and DNA damage caused by ultraviolet rays to epidermal keratinocytes. It is a component widely used as a skin external preparation or supplement expecting these effects.

[0004] A liposome composition encapsulating such ascorbic acid and a method for producing the same have also been proposed (Patent Document 1).

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0006] An object of the present invention is to provide a liposome-containing composition excellent in stability and usability.

Means for Solving the Problems

[0007] As a result of diligent research, the present inventors have found that a composition containing (A) liposomes; and (B) at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen provides good stability and usability, thus completing the present invention.

[0008] In other words, the present invention provides the following compositions. [1] (A) Liposomes; and, (B) A composition containing at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or salt thereof, ginger extract, pomegranate extract, plant and / or extract thereof, oil-coated ascorbic acid and / or salt thereof, hyaluronic acid, ceramide, and collagen. [2] The composition according to [1], wherein part or all of the surface that comes into contact with the composition is housed in a container containing a resin that contains a polyolefin. [3] The composition according to [1], wherein part or all of the surface that comes into contact with the composition is contained in a container containing HPMC (hydroxypropyl methylcellulose) and / or gelatin. [4] (A) Liposomes; and, (B) A composition for reducing adhesion, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. [5] The composition according to [4], wherein the reduction in adhesion is a reduction in adhesion to a layer containing polyolefin, HPMC, or gelatin. [6] (A) Liposomes; and, (B) A discoloration-inhibiting composition containing at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. [7] (A) Liposomes; and, (B) A composition for improving skin moisture content, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. [8] (A) Liposomes; and, (B) A composition for improving collagen score, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. [9] (A) Liposomes; and, (B) A composition for reducing skin redness, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

[10] (A) Liposomes; and, (B) A composition for improving capillaries, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

[11] (A) Liposomes; and, (B) A composition for improving skin smoothness, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

[12] (A) Liposomes; and, (B) A wrinkle-improving composition containing at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

[13] Furthermore, the composition according to any one of [1] to

[12] contains ascorbic acid and / or a salt of ascorbic acid.

[14] The composition according to any one of [1] to

[13] , wherein the plant or extract thereof is one or more selected from the group consisting of Centella asiatica, long pepper, and Job's tears, or an extract thereof.

[15] The composition according to any one of [1] to

[14] , wherein the component (A) is a liposome containing ascorbic acid and / or a salt thereof. [Effects of the Invention]

[0009] According to the present invention, it is possible to provide a composition with good stability and usability. [Mode for Carrying Out the Invention]

[0010] In the present specification, salts include, for example, salts with organic bases (e.g., salts with tertiary amines such as trimethylamine salt, triethylamine salt, monoethanolamine salt, triethanolamine salt, pyridine salt, etc., basic ammonium salts such as arginine salt, etc.), salts with inorganic bases (e.g., alkali metal salts such as ammonium salt, sodium salt, potassium salt, etc., alkaline earth metal salts such as calcium salt, magnesium salt, etc., aluminum salt, etc.).

[0011] In the present specification, salts of ascorbic acid include, for example, alkali metal salts, alkaline earth metal salts and ammonium salts. Examples of the alkali metal salts include sodium salt, potassium salt and lithium salt. Examples of the alkaline earth metal salts include calcium salt and magnesium salt.

[0012] [Composition Containing Liposomes] ((A) Liposomes) The liposomes of the present invention are single- or multi-layered closed vesicles of phospholipids, and may contain desired components in the internal aqueous layer or lipid layer. In this specification, liposomes containing desired components are also referred to as "liposomes". Without limitation, such components included in liposomes include vitamins (e.g., vitamin A [e.g., retinal, retinol, retinoic acid, carotene, dehydroretinal, lycopene, etc.], vitamin B [e.g., thiamine, thiamine disulfide, dicetiamine, octothiamine, cicothiamine, bisibuthiamine, bisbentiamine, prosultiamine, benfotiamine, flursultiamine, riboflavin, flavin adenine dinucleotide, pyridoxine, pyridoxal, hydroxocobalamin, cyanocobalamin, methylcobalamin, deoxyadenocobalamin, folic acid, tetrahydrofolic acid, dihydrofolic acid, nicotinic acid, nicotinamide, nicotinyl alcohol, pantothenic acid, panthenol, biotin, choline, inositol, etc.], vitamin C [e.g., ascorbic acid, salts of ascorbic acid, erythorbic acid, or its derivatives, etc.], vitamin D [e.g., ergocalciferol, cholecalciferol, hydroxycholecalciferol, dihydroxycholecalciferol, dihydrotachysterol, etc.], vitamin E [e.g., tocopherol and its derivatives, ubiquinone derivatives, etc.], other vitamins [e.g., hesperidin, carnitine, ferulic acid, γ-oryzanol, orotic acid, rutin, eriocitrin, etc.]), collagen (including hydrolyzed collagen), hyaluronic acid (including hydrolyzed hyaluronic acid), lactoferrin, polyphenols, etc. Among these, water-soluble vitamins are preferred, water-soluble vitamins containing ascorbic acid and / or its salts, or vitamin B are more preferred, and ascorbic acid and / or its salts are even more preferred.

[0013] The term "encompassed" by a desired component in a liposome means that it is encapsulated within a space within the liposome membrane, present together with the components of the liposome membrane, present between the multiple membranes constituting the liposome, or bound to or attached to the surface of the outermost membrane constituting the liposome.

[0014] The size of liposomes is typically around 30 to 1000 nm, preferably 30 to 600 nm, and more preferably 50 to 200 nm. They may be 1 nm or larger, 5 nm or larger, 10 nm or larger, 50 nm or larger, 100 nm or larger, and may also be 1000 nm or smaller, 500 nm or smaller, 300 nm or smaller, 200 nm or smaller, 100 nm or smaller, etc.

[0015] In this specification, components encapsulated in liposomes may be referred to as "the liposomal component." For example, a water-soluble vitamin encapsulated in liposomes may be referred to as "liposomal water-soluble vitamin," "water-soluble vitamin-encapsulated liposome," "water-soluble vitamin-containing liposome," or "liposomal water-soluble vitamin." Ascorbic acid encapsulated in liposomes may be referred to as "liposomal ascorbic acid," "ascorbic acid-encapsulated liposome," "ascorbic acid-containing liposome," or "liposomal ascorbic acid."

[0016] Liposomes containing the desired components can be produced by conventionally known methods. For example, lecithin and optionally sterols can be solubilized in a solvent such as ethanol, the solvent can be removed under reduced pressure to create a membrane lipid, and then a solution containing the desired components can be added and stirred to prepare a liposome suspension, thereby obtaining liposomes containing the components.

[0017] In addition to the methods described above, liposomes can also be obtained by dissolving lecithin and optionally sterols in a small amount of ethanol, then dispersing them in an aqueous solution or buffer solution for preliminary emulsification, and finally dispersing them under high pressure to form a lipid bilayer and prepare a liposome suspension.

[0018] Liposomes containing water-soluble components are preferred, liposomes containing water-soluble vitamins are more preferred, and liposomes containing ascorbic acid and / or its salts are even more preferred. Such liposomes can be obtained by preparing the water-soluble components as desired components using the method described above. Alternatively, commercially available liposomes can be used. Examples of commercially available liposomes containing ascorbic acid include "Vitamin C Zeal" (manufactured by Aurea Biolabs) and "Lypo-C [Lipocapsule] Vitamin C" (manufactured by Spick).

[0019] The content of the desired component in the liposome containing the desired component is preferably about 10 to 99% by mass, more preferably about 20 to 95% by mass, even more preferably about 25 to 90% by mass, and even more preferably 30 to 70% by mass. It may be 5% or more by mass, 10% or more by mass, 20% or more by mass, 30% or more by mass, 50% or more by mass, 60% or more by mass, and may be 90% or less by mass, 80% or less by mass, 70% or less by mass, 50% or less by mass, or 40% or less by mass.

[0020] For example, the ascorbic acid content in liposomes containing ascorbic acid and / or its salt is preferably about 10 to 99% by mass, more preferably about 20 to 95% by mass, even more preferably about 25 to 90% by mass, and even more preferably 30 to 70% by mass. It may be 5% or more by mass, 10% or more by mass, 20% or more by mass, 30% or more by mass, 50% or more by mass, 60% or more by mass, and may be 90% or less by mass, 80% or less by mass, 70% or less by mass, 50% or less by mass, or 40% or less by mass.

[0021] (A) The content of component (A) is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, even more preferably 0.1% by mass or more, and even more preferably 0.13% by mass or more, based on the total amount of the composition. It may also be 0.5% by mass or more, 1% by mass or more, 2% by mass or more, etc. It may also be 5% by mass or more, 10% by mass or more, etc. Furthermore, the total content of component (A) is preferably 50% by mass or less, more preferably 40% by mass or less, and particularly preferably 30% by mass or less. It may also be 10% by mass or less, 5% by mass or less, 3% by mass or less, etc.

[0022] If the composition is an oral composition, the daily intake of the desired component in component (A), such as ascorbic acid, may vary depending on the individual's condition (weight, age, sex, etc.) and the formulation of the composition. However, from the viewpoint of significantly achieving the effects of the present invention, it is preferably 0.1 mg or more, more preferably 1 mg or more, and even more preferably 3 mg or more. It may also be 10 mg or more, 20 mg or more, or 30 mg or more. It may also be 1000 mg or less, preferably 500 mg or less, more preferably 300 mg or less, and even more preferably 100 mg or less. It may also be 70 mg or less, 50 mg or less, or 40 mg or less.

[0023] (Plants and / or their extracts) The plant and / or extract thereof of the present invention is at least one selected from the group consisting of the whole plant, fruit, flower, leaf, stem, and root, and / or an extract thereof.

[0024] Examples of plants include Centella asiatica, avocado, Hydrangea macrophylla, Long pepper, Angelica keiskei, astaxanthin, American witch hazel, Althaea, Arnica, aloe, apricot, Cimicifuga simplex, Coleus forskohlii, Scutellaria baicalensis leaves, Zanthoxylum piperitum flowers, apricot kernels, Ginkgo biloba, Pyrola incarnata, Arctostaphylos uva-ursi, Nettle, Fennel, Turmeric, Oolong tea, Rosa multiflora, Echinacea leaves, Scutellaria baicalensis, Phellodendron amurense, Coptis japonica, Barley, St. John's wort, Lamium album, Nasturtium officinale, Olive leaves, Kelp, Orange, Catechin, Citrus aurantium, Kumquat, Citrus, Yuzu powder, Chamomile, Carrot, and Kawara Mugwort, licorice, scutellaria, oat, gambir tree, kiwi, cinchona, cucumber, guanosine, gardenia, bamboo grass, Sophora flavescens, walnut, grapefruit, clematis, chlorella, black rice, evening primrose, guava leaves, mulberry, gentian, Geranium thunbergii, burdock, comfrey, collagen, cranberry, water lily, pomegranate, Asarum sieboldii, Bupleurum chinense, salvia, soapwort, bamboo grass, saffron tincture, hawthorn, Japanese pepper, shikwasa, kudzu root, pu-erh tea, shiitake mushroom, Rehmannia glutinosa, Lithospermum erythrorhizon, Perilla, Linden, Spiraea japonica, peony, sweet flag root Ginger, birch, honeysuckle, horsetail, ivy, hawthorn, meadowsweet, rhubarb, tea plant, clove tree, senna, tea, bottle raspberry, tormentilla, elderberry, yarrow, mint, peppermint, sage, mallow, angelica tree, gentian, onion peel, blue flower, soybean, jujube, thyme, angelica sprouts, Chinese artichoke, white kidney bean, Apocynum venetum, tea, clove, cogongrass, dried tangerine peel, angelica, calendula, peach kernel, spruce, houttuynia cordata, tomato, bitter melon, Jerusalem artichoke, barley Young leaves, brown algae, konjac potato, coffee beans, carrots, garlic, wild rose, hibiscus, Ophiopogon, parsley, witch hazel, lotus leaves, Job's tears, rose, parietaria, Isodon japonicus, bisabolol, loquat leaves, coltsfoot, butterbur sprouts, Poria cocos, butcher's broom, grapes, grape seeds, propolis, loofah, safflower, peppermint, linden, peony, hops, pine, horse chestnut, skunk cabbage, soapberry, lemon balsamum, peach, medicinal salvia, Japanese alder, bayberry, cornflower, eucalyptus, saxifrage, coix seed, mugwort, lavender,Examples include apples, lettuce, lemons, lotus flowers, roses, rosemary, logwood, Roman chamomile, and Sanguisorba officinalis. While not limited to these, one or more species selected from the group consisting of Centella asiatica, Long pepper, and Job's tears are preferred.

[0025] Examples of plant extracts include Centella asiatica extract, avocado extract, Hydrangea macrophylla extract, Long pepper extract, Angelica keiskei extract, astaxanthin, American witch hazel, Althaea officinalis extract, Arnica extract, Aloe vera extract, Apricot extract, Cimicifuga simplex extract, Coleus forskohlii extract, Scutellaria baicalensis leaf extract, Zanthoxylum piperitum flower powder, Apricot kernel extract, Ginkgo biloba extract, Pyrola japonica, Arctostaphylos uva-ursi, Nettle extract, Fennel extract, Turmeric extract, Oolong tea extract, Rosa multiflora extract, Echinacea leaf extract, Scutellaria baicalensis extract, Phellodendron amurense extract, Coptis japonica extract, and more. Wheat extract, St. John's wort extract, Lamium album extract, Nasturtium officinale extract, Olive leaf extract, Kelp extract, Orange extract, Catechin, Fortune citrus extract, Bitter orange extract, Fortune citrus extract, Citrus extract, Yuzu powder, Chamomile extract, Carrot extract, Artemisia capillaris extract, Licorice extract, Chloranthus erythrosora extract, Arctium moniliforme extract, Oat extract, Gambier tree extract, Kiwi extract, Cinchona extract, Cucumber extract, Guanosine, Gardenia extract, Sasa veitchii extract, Sophora angustifolia extract, Walnut extract, Grapefruit extract, Clematis extract Kiss extract, chlorella extract, black rice extract, evening primrose extract, guava leaf extract, mulberry extract, gentian extract, geranium extract, burdock extract, comfrey extract, collagen, cranberry extract, water lily, pomegranate, asarum extract, bupleurum extract, salvia extract, soapwort extract, bamboo extract, saffron tincture, hawthorn extract, sansho pepper extract, shikwasa extract, kudzu root extract, pu-erh tea extract, shiitake mushroom extract, rehmannia extract, lithospermum extract, perilla extract, linden extract, meadowsweet extract, peony extract, calamus root Extracts, ginger extract, birch extract, honeysuckle extract, horsetail extract, ivy extract, hawthorn extract, meadowsweet, rhubarb, tea plant, clove plant, senna, tencha, bottle raspberry, tormentilla, elderflower extract, yarrow extract, peppermint extract, mint extract, sage extract, mallow extract, cinnamon extract, swertia japonica extract, onion peel extract, blue flower extract, soybean extract, jujube extract, thyme extract, angelica sprout extract, Chinese artichoke extract,White kidney bean extract, Apocynum venetum extract, tea extract, clove extract, Imperata cylindrica extract, Citrus unshiu peel extract, Angelica acutiloba extract, Calendula officinalis extract, Prunus persica kernel extract, Picea sieboldii extract, Houttuynia cordata extract, Tomato extract, Bitter melon extract, Jerusalem artichoke extract, Barley grass extract, Brown algae extract, Konjac root extract, Coffee bean extract, Carrot extract, Garlic extract, Rosehip extract, Hibiscus extract, Ophiopogon japonicus extract, Parsley extract, Witch hazel extract, Lotus leaf extract, Coix lacryma-jobi extract, Rose extract, Parietaria trifolia extract, Isodon japonicus extract, Bisabolol, Loquat leaf extract, Coltsfoot extract, Butcher's burr extract, Poria cocos extract, Butcher's burr extract, Butcher's burr extract Examples include bloom extract, grape extract, grape seed extract, propolis, loofah extract, safflower extract, peppermint extract, linden extract, peony extract, hop extract, pine extract, horse chestnut extract, skunk cabbage extract, soapberry extract, lemon balm extract, peach extract, sage, alder, bayberry, cornflower extract, eucalyptus extract, saxifrage extract, coix seed extract, mugwort extract, lavender extract, apple extract, lettuce extract, lemon extract, astragalus extract, rose extract, rosemary extract, logwood extract, Roman chamomile extract, burnet extract, and volatile oils from citrus fruits.

[0026] The plant extracts of this invention include Centella asiatica extract, Long pepper extract, Cimicifuga extract, Coleus forskohlii extract, Astragalus membranaceus leaf extract, Zanthoxylum piperitum flower powder, Isodon japonicus extract, Shikuwasa extract, Pu-erh tea extract, Licorice extract, Black rice extract, Evening primrose extract, Guava leaf extract, Loquat leaf extract, Onion peel extract, Blue flower extract, Mulberry leaf extract, Aralia elata sprout extract, Chinese artichoke extract, White kidney bean extract, Apocynum venetum extract, Sasa veitchii extract, Bitter melon extract, Jerusalem artichoke extract, Barley grass extract, Brown algae extract, Konjac extract, Coffee bean extract, Grape seed extract, Apple extract, and Extracts of leaves, kelp, angelica powder, catechin, kumquat extract, bitter orange extract, kumquat extract, citrus extract, yuzu powder and citrus peel extract; extracts of witch hazel, apricot, wintergreen, bearberry, cowpea, crape myrtle, gambier, geranium, water lily, pomegranate, peony, meadowsweet, rhubarb, tea plant, clove, senna, tea, bottle strawberry, tormentilla, rose, peony, medulis, alder, bayberry, eucalyptus, logwood, and burnet; volatile oils of citrus fruits are preferred. Although not limited, one or more selected from the group consisting of centella asiatica extract, long pepper extract, and coix seed extract are particularly preferred.

[0027] (Centella Asiatica Extract) When using Centella asiatica extract as a plant extract, it is preferable that it be at least one extract selected from the group consisting of the whole plant, fruit, flower, leaf, stem, and root, more preferably an extract of the leaf and / or stem, and even more preferably an extract of the leaf. For extraction, solvents such as water, methanol, ethanol, and isopropanol can be used. Commercially available Centella asiatica extract may also be used.

[0028] (Long Pepper Extract) When using long pepper extract as a plant extract, it is preferable that it be at least one extract selected from the group consisting of the whole plant, fruit, flower, leaf, stem, and root, and more preferably an extract of the fruit (fruit cluster). For example, it can be obtained by concentrating the juice or extract obtained from the fruit by methods such as pressing or solvent extraction. Solvents such as water, methanol, ethanol, and isopropanol can be used for extraction. Commercially available long pepper extract may also be used.

[0029] (Job's Tears Extract) When using Job's tears extract as a plant extract, it is preferable that it be at least one extract selected from the group consisting of the whole plant, fruit, flower, leaf, stem, and root, and more preferably an extract of the fruit. For example, it can be obtained by concentrating the juice or extract obtained from the fruit by methods such as pressing or solvent extraction. It may also be an extract obtained from polished Job's tears, or an extract obtained by crushing Job's tears with the hulls intact and then treating it with enzymes. Solvents such as water, methanol, ethanol, and isopropanol can be used. Commercially available Job's tears extract may also be used.

[0030] (Content) From the viewpoint of significantly achieving the effects of the present invention, the content of plants and / or their extracts is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, and particularly preferably 0.01% by mass or more, based on the total amount of the composition. It may also be 0.05% by mass or more, 0.1% by mass or more, 0.15% by mass or more, etc. Furthermore, the content of plants and / or their extracts is preferably 50% by mass or less, more preferably 20% by mass or less, and particularly preferably 10% by mass or less. It may also be 7% by mass or less, 4% by mass or less, 2% by mass or less, etc.

[0031] For example, from the viewpoint of significantly exhibiting the effects of the present invention, the content of Centella asiatica extract is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, and particularly preferably 0.01% by mass or more, based on the total amount of the composition. The content of Centella asiatica extract may also be 0.05% by mass or more, 0.1% by mass or more, 0.15% by mass or more, etc. Furthermore, the content of Centella asiatica extract is preferably 50% by mass or less, more preferably 20% by mass or less, and particularly preferably 10% by mass or less. It may also be 7% by mass or less, 4% by mass or less, 2% by mass or less, etc.

[0032] In the case of Centella asiatica extract, the ratio of crude drugs is usually 1 to 100:1, preferably 5 to 50:1, more preferably 7 to 20:1, and even more preferably 10 to 15:1 (1 kg of extract can be obtained from 10 kg to 15 kg of leaves). Furthermore, the total content of asiatic acid, madecassic acid, madecassoside, and asiaticoside is preferably 5% by mass or more, more preferably 10% by mass or more, even more preferably 20% by mass or more, even more preferably 30% by mass or more, and particularly preferably 45% by mass or more.

[0033] For example, from the viewpoint of significantly exhibiting the effects of the present invention, the content of long pepper extract is preferably 0.0001% by mass or more, more preferably 0.0005% by mass or more, and particularly preferably 0.001% by mass or more, based on the total amount of the composition. The content of long pepper extract may also be 0.005% by mass or more, 0.01% by mass or more, 0.02% by mass or more, etc. The content of long pepper extract is preferably 30% by mass or less, more preferably 10% by mass or less, and particularly preferably 5% by mass or less. It may also be 2% by mass or less, 0.1% by mass or less, 0.05% by mass or less, etc.

[0034] For example, from the viewpoint of significantly exhibiting the effects of the present invention, the content of Job's tears extract is preferably 0.1% by mass or more, more preferably 1% by mass or more, and particularly preferably 2% by mass or more, based on the total amount of the composition. The Job's tears extract content may also be 0.01% by mass or more, 0.05% by mass or more, 0.001% by mass or more, etc. Furthermore, the Job's tears extract content is preferably 75% by mass or less, more preferably 50% by mass or less, and particularly preferably 35% by mass or less. It may also be 20% by mass or less, 10% by mass or less, 5% by mass or less, 1% by mass or less, 0.5% by mass or less, 0.1% by mass or less, etc.

[0035] From the viewpoint of significantly achieving the effects of the present invention, when Centella asiatica is used, its content is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, and particularly preferably 0.1% by mass or more, based on the total amount of the composition. The Centella asiatica content may also be 0.001% by mass or more, 0.005% by mass or more, 0.03% by mass or more, 0.5% by mass or more, 1% by mass or more, etc. Furthermore, the Centella asiatica content is preferably 95% by mass or less, more preferably 40% by mass or less, and particularly preferably 20% by mass or less. It may also be 70% by mass or less, 60% by mass or less, 30% by mass or less, 10% by mass or less, 2% by mass or less, etc.

[0036] From the viewpoint of significantly achieving the effects of the present invention, the content of long pepper is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, and particularly preferably 0.01% by mass or more, based on the total amount of the composition. The content of long pepper extract may also be 0.05% by mass or more, 0.1% by mass or more, 0.2% by mass or more, etc. Furthermore, the content of long pepper is preferably 90% by mass or less, more preferably 40% by mass or less, and particularly preferably 20% by mass or less. It may also be 10% by mass or less, 5% by mass or less, 1% by mass or less, etc.

[0037] For example, from the viewpoint of significantly achieving the effects of the present invention, the adlay content is preferably 1% by mass or more, more preferably 10% by mass or more, and particularly preferably 20% by mass or more, based on the total amount of the composition. The adlay content may also be 0.1% by mass or more, 0.5% by mass or more, 0.01% by mass or more, etc. The adlay content is also preferably 60% by mass or less, more preferably 40% by mass or less, and particularly preferably 20% by mass or less. It may also be 10% by mass or less, 5% by mass or less, 1% by mass or less, etc.

[0038] Here, the content of plants and / or their extracts, Centella asiatica, long pepper, Job's tears, Centella asiatica extract, long pepper extract, and Job's tears extract all refer to the dry solids content.

[0039] The daily intake of plants and / or their extracts may vary depending on the individual's condition (weight, age, sex, etc.) and the formulation of the composition. However, from the viewpoint of significantly achieving the effects of the present invention, it is preferable, for example, to be 0.01 mg or more, more preferably 0.1 mg or more, and even more preferably 0.5 mg or more. It may also be 3 mg or more, 5 mg or more, or 10 mg or more. It may also be less than or equal to 100 mg, preferably 500 mg or less, more preferably 300 mg or less, and even more preferably 100 mg or less. It may also be 70 mg or less, 40 mg or less, or 20 mg or less.

[0040] (Ascorbic acid and / or salts thereof coated with oil or fat) The oil-coated ascorbic acid and / or its salts of the present invention are, but are not limited to, obtained by coating ascorbic acid and / or its salts with animal-derived oils or vegetable oils. As oils, for example, hydrogenated oils can be preferably used. Examples include vegetable oils such as hydrogenated soybean oil, rice bran wax, or hydrogenated seed oil, and animal oils such as hydrogenated beef tallow. These oils may also be powdered oils whose surfaces have been previously coated with a hydrophilic material.

[0041] Coating oils for ascorbic acid and / or its salts can be produced by conventionally known methods. For example, they can be prepared using conventional coating methods such as rolling granulation, extrusion granulation, compression granulation, fluid granulation, crushing granulation, agitation granulation, and melt mixing.

[0042] Commercially available products can also be used as oil-coated ascorbic acid and / or its salts. Examples of commercially available products include "VC-80R" (manufactured by NOF Corporation), "Ascorbic Acid-95R" (manufactured by NOF Corporation), and "Vitacoat C-95" (manufactured by Yokohama Oil & Fat Industry Co., Ltd.).

[0043] The ratio of coating oil to ascorbic acid and / or its salt is preferably 1% to 70% by mass, more preferably 2 to 50% by mass, even more preferably 3 to 30% by mass, and even more preferably 5 to 20% by mass of the oil-coated ascorbic acid and / or its salt. It may be 1% or more by mass, 3% or more by mass, 4% or more by mass, and may also be 50% or less by mass, 30% or less by mass, 20% or less by mass, 10% or less by mass, etc.

[0044] From the viewpoint of significantly achieving the effects of the present invention, the content of oil-coated ascorbic acid and / or its salt is preferably 0.1% by mass or more, more preferably 0.3% by mass or more, and particularly preferably 0.5% by mass or more, based on the total amount of the composition. It may also be 1% by mass or more, 1.5% by mass or more, 2% by mass or more, etc. Furthermore, the content is preferably 95% by mass or less, more preferably 93% by mass or less, and particularly preferably 90% by mass or less. It may also be 20% by mass or less, 10% by mass or less, 5% by mass or less, etc.

[0045] (Hyaluronic acid) The hyaluronic acid of the present invention is not limited in its origin or molecular weight, and can be extracted from animal tissue or produced by fermentation using microbial culture. Commercially available hyaluronic acid can also be used. The hyaluronic acid may have an average molecular weight of approximately 500,000 to 3,000,000, approximately 10,000 to 500,000, or even an average molecular weight of 10,000 or less.

[0046] From the viewpoint of significantly achieving the effects of the present invention, the hyaluronic acid content is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more, based on the total amount of the composition. It may also be 0.01% by mass or more, 0.005% by mass or more, 0.001% by mass or more, etc. Furthermore, the content is preferably 10% by mass or less, more preferably 5% by mass or less, and particularly preferably 2% by mass or less. It may also be 20% by mass or less, 40% by mass or less, 60% by mass or less, etc.

[0047] (Ceramide) The ceramides of the present invention include sphingosine, phytosphingosine, ceramides in which a fatty acid is amide-bonded to sphingosine, sphingoglycolipids in which sugar is bonded to ceramide (typically cerebrosides), sphingophospholipids in which phosphate and a base are bonded to ceramide (typically sphingomyelins), synthetic ceramides having a structure similar to ceramide (such as N-(hexadecyloxyhydroxypropyl)-N-hydroxyethylhexadecanamide, hexadecyloxyPG-hydroxyethylhexadecanamide, and cetylPG-hydroxyethylpalmitamide), human-type ceramides obtained by fermentation by yeast, etc. (for example, ceramide 2, ceramide 3, and fermented ceramide), animal-derived ceramides extracted from animal spinal cords and brains, plant-derived ceramides extracted from rice, soybeans, corn, wheat, etc., and any of ceramides 1 to 10. Ceramides can be used individually or in combination of two or more types.

[0048] From the viewpoint of significantly achieving the effects of the present invention, the ceramide content is preferably 0.03% by mass or more, more preferably 0.04% by mass or more, and particularly preferably 0.05% by mass or more, based on the total amount of the composition. It may also be 0.01% by mass or more, 0.005% by mass or more, 0.001% by mass or more, etc. Furthermore, the content is preferably 1.5% by mass or less, more preferably 1% by mass or less, and particularly preferably 0.2% by mass or less. It may also be 2% by mass or less, 5% by mass or less, 10% by mass or less, etc.

[0049] (collagen) The collagen of the present invention is not limited in its origin or molecular weight, and may include fish-derived collagen, porcine-derived collagen, bovine-derived collagen, atelocollagen, collagen-degraded peptides, hydrolyzed collagen, and hydroxypropylammonium chloride hydrolyzed collagen. Among these, fish-derived collagen, porcine-derived collagen, and bovine-derived collagen are preferred.

[0050] From the viewpoint of significantly achieving the effects of the present invention, the collagen content is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more, based on the total amount of the composition. It may also be 1% by mass or more, 5% by mass or more, 10% by mass or more, etc. Furthermore, the content is preferably 95% by mass or less, more preferably 93% by mass or less, and particularly preferably 90% by mass or less. It may also be 40% by mass or less, 30% by mass or less, 25% by mass or less, etc.

[0051] (Glutathione) The glutathione of the present invention is a type of amino acid, and its origin and molecular weight are not limited. It may be yeast-derived (e.g., bread), liver-derived (e.g., pork), or meat-derived (e.g., beef, pork), or it may be a synthetic product. While not limited, yeast-derived glutathione is preferred, and it may be in the form of a yeast extract containing glutathione. The form of the yeast extract is not limited, but it is preferably in the form of an extract powder or a powder. It is preferable that the yeast extract contains 5-50% glutathione. A commercially available product is Hi-Thion Extract YH-D20 (Mitsubishi Corporation Life Science, 20% or more glutathione).

[0052] From the viewpoint of significantly exhibiting the effects of the present invention, the glutathione content is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more, based on the total amount of the composition. It may also be 1% by mass or more, 5% by mass or more, 10% by mass or more, etc. Furthermore, the content is preferably 90% by mass or less, more preferably 70% by mass or less, and particularly preferably 50% by mass or less. It may also be 40% by mass or less, 30% by mass or less, 20% by mass or less, etc. When glutathione is included as an extract, for example, based on the total amount of the composition, it is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more. It may also be 1% by mass or more, 5% by mass or more, 10% by mass or more, etc. Furthermore, the content is preferably 90% by mass or less, more preferably 70% by mass or less, and particularly preferably 50% by mass or less. Furthermore, the amount may be 40% by mass or less, 30% by mass or less, 20% by mass or less, etc.

[0053] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of glutathione to component (A) is preferably 0.05 parts by mass or more, more preferably 0.1 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 1 part by mass of component (A). It may also be 0.005 parts by mass or more, 1 part by mass or more, 5 parts by mass or more, 10 parts by mass or more, 100 parts by mass or more, etc. Furthermore, the content is preferably 90 parts by mass or less, more preferably 70 parts by mass or less, and particularly preferably 50 parts by mass or less. It may also be 400 parts by mass or less, 40 parts by mass or less, 30 parts by mass or less, 20 parts by mass or less, 5 parts by mass or less, 1 part by mass or less, etc.

[0054] (Nicotinamide mononucleotide) The nicotinamide mononucleotide (NMN) of the present invention is a compound derived from vitamin B3 (niacin). Its origin is not limited, and it may be a synthetic product, but it is mainly produced using fermentation technology by microorganisms (yeast or certain bacteria) or enzymatic reactions produced by microorganisms. While not limited, yeast-derived nicotinamide mononucleotide is preferred, and it may be in the form of a yeast extract containing nicotinamide mononucleotide. While not limited to a specific form, an extract powder or powder form is preferred. It is preferable that the yeast extract contains 50% or more nicotinamide mononucleotide, and it may also contain 70% or more, or 90% or more. A commercially available product is fermented NMN (Nippon Bulk Pharmaceuticals, 99%).

[0055] From the viewpoint of significantly achieving the effects of the present invention, the content of nicotinamide mononucleotide is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more, based on the total amount of the composition. It may also be 1% by mass or more, 5% by mass or more, 10% by mass or more, etc. Furthermore, the content is preferably 90% by mass or less, more preferably 50% by mass or less, and particularly preferably 30% by mass or less. It may also be 20% by mass or less, 15% by mass or less, 10% by mass or less, etc. When nicotinamide mononucleotide is included as an extract, for example, based on the total amount of the composition, it is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more. It may also be 1% by mass or more, 5% by mass or more, 10% by mass or more, etc. Furthermore, the content is preferably 90% by mass or less, more preferably 70% by mass or less, and particularly preferably 50% by mass or less. Furthermore, the amount may be 40% by mass or less, 30% by mass or less, 20% by mass or less, etc.

[0056] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of nicotinamide mononucleotide to component (A) is preferably 0.05 parts by mass or more, more preferably 0.1 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 1 part by mass of component (A). It may also be 0.005 parts by mass or more, 1 part by mass or more, 5 parts by mass or more, 10 parts by mass or more, etc. Furthermore, the content is preferably 90 parts by mass or less, more preferably 50 parts by mass or less, and particularly preferably 30 parts by mass or less. It may also be 900 parts by mass or less, 500 parts by mass or less, 20 parts by mass or less, 15 parts by mass or less, 10 parts by mass or less, 1 part by mass or less, etc.

[0057] (Pyrroloquinoline quinone and / or salts thereof) The pyrroloquinoline quinone and / or salt thereof of the present invention are also present in trace amounts in fermented foods, vegetables, fruits, legumes, green tea, etc. While the origin is not limited and it may be a synthetic product, it is mainly produced using fermentation technology involving microorganisms (yeast or certain bacteria) or enzymatic reactions produced by microorganisms. As the salt of pyrroloquinoline quinone, pyrroloquinoline quinone disodium salt is preferred.

[0058] From the viewpoint of significantly achieving the effects of the present invention, the content of pyrroloquinoline quinone or its salt is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, and particularly preferably 0.1% by mass or more, based on the total amount of the composition. It may also be 1% by mass or more, 5% by mass or more, etc. Furthermore, the content is preferably 30% by mass or less, more preferably 10% by mass or less, and particularly preferably 5% by mass or less. It may also be 1% by mass or less, 0.5% by mass or less, etc.

[0059] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of pyrroloquinoline quinone to component (A) is preferably 0.05 parts by mass or more, more preferably 0.1 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 1 part by mass of component (A). It may also be 0.005 parts by mass or more, 1 part by mass or more, 5 parts by mass or more, 10 parts by mass or more, etc. Furthermore, the content is preferably 90 parts by mass or less, more preferably 50 parts by mass or less, and particularly preferably 30 parts by mass or less. It may also be 20 parts by mass or less, 15 parts by mass or less, 10 parts by mass or less, 1 part by mass or less, etc.

[0060] (Water chestnut extract) This is an extract of the fruit peel (Turmeric pulp) of a plant of the genus Trapa genus, and its main component is Trapa pulp polyphenols. When using Trapa pulp extract, solvents such as water, methanol, ethanol, and isopropanol can be used for extraction, and are not limited to these, but water is preferred. The form is not limited, but extract powder or powder form is preferred. Commercially available Trapa pulp extract may also be used, such as Trapa pulp extract (Hayashikane Sangyo, Trapa pulp extract 67%).

[0061] From the viewpoint of significantly achieving the effects of the present invention, the content of water chestnut extract is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more, based on the total amount of the composition. It may also be 1% by mass or more, 5% by mass or more, 10% by mass or more, etc. Furthermore, the content is preferably 90% by mass or less, more preferably 50% by mass or less, and particularly preferably 30% by mass or less. It may also be 20% by mass or less, 15% by mass or less, 10% by mass or less, etc.

[0062] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of water chestnut extract to component (A) is preferably 0.05 parts by mass or more, more preferably 0.1 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 1 part by mass of component (A). It may also be 0.005 parts by mass or more, 1 part by mass or more, 5 parts by mass or more, 10 parts by mass or more, etc. Furthermore, the content is preferably 90 parts by mass or less, more preferably 50 parts by mass or less, and particularly preferably 30 parts by mass or less. It may also be 900 parts by mass or less, 500 parts by mass or less, 20 parts by mass or less, 15 parts by mass or less, 10 parts by mass or less, 1 part by mass or less, etc.

[0063] (Placenta) As placenta, extracts from mammals such as humans, pigs, and horses, or fish such as salmon, can be used, with placenta extracts (placenta extract) derived from salmon ovarian membrane or pig placenta being preferred. Conventional extraction methods can be used, and various forms such as liquid, powder, solid, and granular can be used. While not limited to these, powder form is preferred in this invention.

[0064] From the viewpoint of significantly achieving the effects of the present invention, the content of placenta or its salt is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more, based on the total amount of the composition. It may also be 1% by mass or more, 5% by mass or more, 10% by mass or more, etc. Furthermore, the content is preferably 90% by mass or less, more preferably 50% by mass or less, and particularly preferably 30% by mass or less. It may also be 20% by mass or less, 15% by mass or less, 10% by mass or less, etc.

[0065] In the present invention, from the viewpoint of more significantly demonstrating the effects of the present invention, the ratio of placenta to component (A) is preferably 0.05 parts by mass or more, more preferably 0.1 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 1 part by mass of component (A). It may also be 0.005 parts by mass or more, 1 part by mass or more, 5 parts by mass or more, 10 parts by mass or more, etc. Furthermore, the content is preferably 90 parts by mass or less, more preferably 50 parts by mass or less, and particularly preferably 30 parts by mass or less. It may also be 900 parts by mass or less, 500 parts by mass or less, 20 parts by mass or less, 15 parts by mass or less, 10 parts by mass or less, 1 part by mass or less, etc.

[0066] (Pomegranate extract) The "pomegranate extract" used in this invention can be extracted from pomegranates, and can be prepared from the fruit, seeds, or peel in particular. Water, ethanol, etc., can be used as the extraction solvent. The solvent-extracted pomegranate extract is not limited, but a powder such as extract powder is preferred. The pomegranate extract used is preferably concentrated with polyphenols at 30% or more, and more preferably at 50% or more. Among the polyphenols, it is particularly preferable that ellagic acid is concentrated at 80% or more. Commercial products that can be used include, for example, pomegranate ellagic acid (Sabinsa Japan Corporation) and pomegranate extract powder 10 (13.1%, Ikeda Sugar Refining Co., Ltd.).

[0067] The pomegranate extract content used in the present invention is not particularly limited, but for example, based on the total amount of the composition, it is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more. It may also be 1% by mass or more, 5% by mass or more, 10% by mass or more, etc. Furthermore, the content is preferably 90% by mass or less, more preferably 50% by mass or less, and particularly preferably 30% by mass or less. It may also be 20% by mass or less, 15% by mass or less, 10% by mass or less, 1% by mass or less, etc.

[0068] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of pomegranate extract to component (A) is preferably 0.05 parts by mass or more, more preferably 0.1 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 1 part by mass of component (A). It may also be 0.005 parts by mass or more, 1 part by mass or more, 5 parts by mass or more, 10 parts by mass or more, etc. Furthermore, the content is preferably 90 parts by mass or less, more preferably 50 parts by mass or less, and particularly preferably 30 parts by mass or less. It may also be 900 parts by mass or less, 500 parts by mass or less, 20 parts by mass or less, 15 parts by mass or less, 10 parts by mass or less, 1 part by mass or less, etc.

[0069] (Ginger extract) The "ginger extract" used in this invention is a concentrated extract of components obtained from the rhizome of ginger (Zingiber officinale), and water, ethanol, etc., can be used as the extraction solvent. The solvent-extracted ginger extract is not limited, but a powder such as extract powder is preferred. As a commercially available product, for example, ginger extract (product name: GINGER EXTRACT 40%: Bio Actives Japan) can be used.

[0070] The ginger extract content used in the present invention is not particularly limited, but for example, based on the total amount of the composition, it is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and particularly preferably 0.5% by mass or more. It may also be 1% by mass or more, 5% by mass or more, 10% by mass or more, etc. Furthermore, the content is preferably 90% by mass or less, more preferably 50% by mass or less, and particularly preferably 30% by mass or less. It may also be 20% by mass or less, 15% by mass or less, 10% by mass or less, 1% by mass or less, etc.

[0071] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of ginger extract to component (A) is preferably 0.05 parts by mass or more, more preferably 0.1 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 1 part by mass of component (A). It may also be 0.005 parts by mass or more, 1 part by mass or more, 5 parts by mass or more, 10 parts by mass or more, etc. Furthermore, the content is preferably 90 parts by mass or less, more preferably 50 parts by mass or less, and particularly preferably 30 parts by mass or less. It may also be 900 parts by mass or less, 500 parts by mass or less, 20 parts by mass or less, 15 parts by mass or less, 10 parts by mass or less, 1 part by mass or less, etc.

[0072] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of oil-coated ascorbic acid and / or its salt to component (A) is preferably 0.01 parts by mass or more, more preferably 0.05 parts by mass or more, even more preferably 0.1 parts by mass or more, even more preferably 0.3 parts by mass or more, particularly preferably 0.5 parts by mass or more, and most preferably 1 part by mass or more, per 1 part by mass of component (A). It may also be 5 parts by mass or more, 10 parts by mass or more, 20 parts by mass or more, 50 parts by mass or more, 100 parts by mass or more, etc. Furthermore, the content of oil-coated ascorbic acid and / or its salt per 1 part by mass of component (A) is preferably 300 parts by mass or less, more preferably 400 parts by mass or less, even more preferably 500 parts by mass or less, particularly preferably 600 parts by mass or less, and most preferably 700 parts by mass or less. The amount may be 300 parts by mass or less, 100 parts by mass or less, 50 parts by mass or less, 20 parts by mass or less, 10 parts by mass or less, 5 parts by mass or less, 1 part by mass or less, etc.

[0073] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of Centella asiatica extract to component (A) is preferably 0.00001 parts by mass or more, more preferably 0.00005 parts by mass or more, even more preferably 0.0001 parts by mass or more, even more preferably 0.0003 parts by mass or more, particularly preferably 0.0005 parts by mass or more, and most preferably 0.001 parts by mass or more, per 1 part by mass of component (A). It may also be 0.01 parts by mass or more, 0.05 parts by mass or more, 0.1 parts by mass or more, 0.5 parts by mass or more, 1 part by mass or more, etc. Furthermore, the content of Centella asiatica extract per 1 part by mass of component (A) is preferably 40 parts by mass or less, more preferably 30 parts by mass or less, even more preferably 25 parts by mass or less, even more preferably 20 parts by mass or less, particularly preferably 15 parts by mass or less, and most preferably 10 parts by mass or less. It may be 5 parts by mass or less, 1 part by mass or less, 0.5 parts by mass or less, 0.1 parts by mass or less, 0.05 parts by mass or less, 0.01 parts by mass or less, etc.

[0074] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of long pepper extract to component (A) is preferably 0.00001 parts by mass or more, more preferably 0.0001 parts by mass or more, even more preferably 0.0003 parts by mass or more, even more preferably 0.0005 parts by mass or more, particularly preferably 0.001 parts by mass or more, and most preferably 0.003 parts by mass or more, per 1 part by mass of component (A). It may also be 0.01 parts by mass or more, 0.05 parts by mass or more, 0.1 parts by mass or more, 0.5 parts by mass or more, 1 part by mass or more, etc. Furthermore, the content of long pepper extract per 1 part by mass of component (A) is preferably 40 parts by mass or less, more preferably 30 parts by mass or less, even more preferably 20 parts by mass or less, even more preferably 15 parts by mass or less, particularly preferably 10 parts by mass or less, and most preferably 5 parts by mass or less. It may be 1 part by mass or less, 0.5 parts by mass or less, 0.1 parts by mass or less, 0.05 parts by mass or less, 0.01 parts by mass or less, etc.

[0075] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of Job's tears extract to component (A) is preferably 0.0001 parts by mass or more, more preferably 0.0003 parts by mass or more, even more preferably 0.0005 parts by mass or more, even more preferably 0.001 parts by mass or more, particularly preferably 0.003 parts by mass or more, and most preferably 0.01 parts by mass or more, per 1 part by mass of component (A). It may also be 0.05 parts by mass or more, 0.1 parts by mass or more, 0.5 parts by mass or more, 1 part by mass or more, etc. Furthermore, the content of Job's tears extract per 1 part by mass of component (A) is preferably 70 parts by mass or less, more preferably 60 parts by mass or less, even more preferably 50 parts by mass or less, even more preferably 40 parts by mass or less, particularly preferably 35 parts by mass or less, and most preferably 30 parts by mass or less. The amount may be 20 parts by mass or less, 10 parts by mass or less, 5 parts by mass or less, 1 part by mass or less, 0.5 parts by mass or less, 0.1 parts by mass or less, 0.05 parts by mass or less, 0.01 parts by mass or less, etc.

[0076] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of hyaluronic acid to component (A) is preferably 0.0001 parts by mass or more, more preferably 0.0003 parts by mass or more, even more preferably 0.0005 parts by mass or more, even more preferably 0.001 parts by mass or more, particularly preferably 0.003 parts by mass or more, and most preferably 0.01 parts by mass or more, per 1 part by mass of component (A). It may also be 0.05 parts by mass or more, 0.1 parts by mass or more, 0.5 parts by mass or more, 1 part by mass or more, 10 parts by mass or more, etc. Furthermore, the content of hyaluronic acid per 1 part by mass of component (A) is preferably 65 parts by mass or less, more preferably 55 parts by mass or less, even more preferably 45 parts by mass or less, even more preferably 35 parts by mass or less, particularly preferably 25 parts by mass or less, and most preferably 15 parts by mass or less. The amount may be 10 parts by mass or less, 5 parts by mass or less, 1 part by mass or less, 0.5 parts by mass or less, 0.1 parts by mass or less, 0.05 parts by mass or less, 0.01 parts by mass or less, etc.

[0077] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of ceramide to component (A) is preferably 0.00003 parts by mass or more, more preferably 0.00005 parts by mass or more, even more preferably 0.0001 parts by mass or more, even more preferably 0.0003 parts by mass or more, particularly preferably 0.0005 parts by mass or more, and most preferably 0.001 parts by mass or more, per 1 part by mass of component (A). It may also be 0.01 parts by mass or more, 0.05 parts by mass or more, 0.1 parts by mass or more, 0.5 parts by mass or more, 1 part by mass or more, 10 parts by mass or more, etc. Furthermore, the content of hyaluronic acid per 1 part by mass of component (A) is preferably 20 parts by mass or less, more preferably 10 parts by mass or less, even more preferably 5 parts by mass or less, even more preferably 3 parts by mass or less, particularly preferably 1 part by mass or less, and most preferably 0.5 parts by mass or less. It may be 0.1 parts by mass or less, 0.05 parts by mass or less, 0.01 parts by mass or less, etc.

[0078] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of collagen to component (A) is preferably 0.0005 parts by mass or more, more preferably 0.001 parts by mass or more, even more preferably 0.005 parts by mass or more, even more preferably 0.01 parts by mass or more, particularly preferably 0.05 parts by mass or more, and most preferably 0.1 parts by mass or more, per 1 part by mass of component (A). It may also be 0.5 parts by mass or more, 1 part by mass or more, 10 parts by mass or more, 20 parts by mass or more, etc. Furthermore, the collagen content per 1 part by mass of component (A) is preferably 2000 parts by mass or less, more preferably 1500 parts by mass or less, even more preferably 1200 parts by mass or less, even more preferably 1000 parts by mass or less, particularly preferably 700 parts by mass or less, and most preferably 500 parts by mass or less. It may be 250 parts by mass or less, 100 parts by mass or less, 50 parts by mass or less, 20 parts by mass or less, 10 parts by mass or less, 5 parts by mass or less, 1 part by mass or less, 0.5 parts by mass or less, 0.1 parts by mass or less, 0.05 parts by mass or less, 0.01 parts by mass or less.

[0079] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of Centella asiatica to component (A) is preferably 0.0001 parts by mass or more, more preferably 0.0005 parts by mass or more, even more preferably 0.001 parts by mass or more, even more preferably 0.003 parts by mass or more, particularly preferably 0.005 parts by mass or more, and most preferably 0.01 parts by mass or more, per 1 part by mass of component (A). It may also be 0.1 parts by mass or more, 0.5 parts by mass or more, 1 part by mass or more, 10 parts by mass or more, etc. Furthermore, the content of Centella asiatica per 1 part by mass of component (A) is preferably 400 parts by mass or less, more preferably 300 parts by mass or less, even more preferably 250 parts by mass or less, even more preferably 200 parts by mass or less, particularly preferably 150 parts by mass or less, and most preferably 100 parts by mass or less. The amount may be 50 parts by mass or less, 20 parts by mass or less, 10 parts by mass or less, 5 parts by mass or less, 1 part by mass or less, 0.5 parts by mass or less, 0.1 parts by mass or less, 0.05 parts by mass or less, 0.01 parts by mass or less.

[0080] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of long pepper to component (A) is preferably 0.0001 parts by mass or more, more preferably 0.001 parts by mass or more, even more preferably 0.003 parts by mass or more, even more preferably 0.005 parts by mass or more, particularly preferably 0.01 parts by mass or more, and most preferably 0.03 parts by mass or more, per 1 part by mass of component (A). It may also be 0.1 parts by mass or more, 0.5 parts by mass or more, 1 part by mass or more, 10 parts by mass or more, etc. Furthermore, the content of long pepper per 1 part by mass of component (A) is preferably 400 parts by mass or less, more preferably 300 parts by mass or less, even more preferably 200 parts by mass or less, even more preferably 150 parts by mass or less, particularly preferably 100 parts by mass or less, and most preferably 50 parts by mass or less. The amount may be 20 parts by mass or less, 10 parts by mass or less, 5 parts by mass or less, 1 part by mass or less, 0.5 parts by mass or less, 0.1 parts by mass or less, 0.05 parts by mass or less, 0.01 parts by mass or less, etc.

[0081] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of Job's tears to component (A) is preferably 0.001 parts by mass or more, more preferably 0.003 parts by mass or more, even more preferably 0.005 parts by mass or more, even more preferably 0.01 parts by mass or more, particularly preferably 0.03 parts by mass or more, and most preferably 0.1 parts by mass or more, per 1 part by mass of component (A). It may also be 0.5 parts by mass or more, 1 part by mass or more, 10 parts by mass or more, etc. Furthermore, the content of Job's tears extract per 1 part by mass of component (A) is preferably 700 parts by mass or less, more preferably 600 parts by mass or less, even more preferably 500 parts by mass or less, even more preferably 400 parts by mass or less, particularly preferably 350 parts by mass or less, and most preferably 300 parts by mass or less. The amount may be 100 parts by mass or less, 50 parts by mass or less, 20 parts by mass or less, 10 parts by mass or less, 5 parts by mass or less, 1 part by mass or less, 0.5 parts by mass or less, 0.1 parts by mass or less, 0.05 parts by mass or less, 0.01 parts by mass or less.

[0082] (Other ingredients) The compositions of the present invention may contain pharmacologically active or physiologically active components other than components (A) and (B), as long as they do not impair the effects of the present invention. These pharmacologically active or physiologically active components may be used individually or in combination of two or more. Such components include, but are not limited to, various vitamins and peptides.

[0083] Here, vitamins include, for example, vitamin A compounds [e.g., retinal, retinol, retinoic acid, carotene, dehydroretinal, lycopene, etc.], vitamin B compounds [e.g., thiamine, thiamine disulfide, dicethiamine, octothiamine, shikotiamine, bisibthiamine, bisbentiamine, prosultiamine, benfotiamine, fursultiamine, riboflavin, flavin adenine dinucleotide, pyridoxine, pyridoxal, hydroxocobalamin, cyanocobalamin, methylcobalamin, deoxyadenocobalamin, folic acid, tetrahydrofolate, dihydrofolate, nicotinic acid, nicotinamide, nicotinic acid]. Examples include thyroidyl alcohol, pantothenic acid, panthenol, biotin, choline, inositol, etc., vitamin C derivatives [e.g., ascorbic acid, salts of ascorbic acid, erythorbic acid, or derivatives thereof], vitamin D derivatives [e.g., ergocalciferol, cholecalciferol, hydroxycholecalciferol, dihydroxycholecalciferol, dihydrotachisterol, etc.], vitamin E derivatives [e.g., tocopherol and its derivatives, ubiquinone derivatives, etc.], and other vitamins [e.g., hesperidin, carnitine, ferulic acid, γ-oryzanol, orotic acid, rutin, eriocitrin, etc.]. Of these, water-soluble vitamins are preferred, water-soluble vitamins containing ascorbic acid and / or its salts, or vitamin B derivatives are more preferred, and ascorbic acid and / or its salts are even more preferred. A combination of ascorbic acid and a salt of ascorbic acid is particularly preferred, and a combination of ascorbic acid and sodium ascorbate is most preferred. Note that the terms "ascorbic acid" and "salts of ascorbic acid" used here refer to ascorbic acid in its original form, not in a form encapsulated in liposomes or coated with lipids.

[0084] Here, for example, the content of ascorbic acid and / or its salt present in its original form is preferably 1% by mass or more, more preferably 3% by mass or more, and particularly preferably 5% by mass or more, based on the total amount of the composition, from the viewpoint of significantly achieving the effects of the present invention. It may also be 10% by mass or more, 20% by mass or more, 30% by mass or more, etc. It may also be 50% by mass or more, 60% by mass or more. Furthermore, the content is preferably 99% by mass or less, more preferably 97% by mass or less, and particularly preferably 95% by mass or less. It may also be 80% by mass or less, 70% by mass or less, 60% by mass or less, etc. It may also be 50% by mass or less, 30% by mass or less.

[0085] In the present invention, from the viewpoint of more significantly exhibiting the effects of the present invention, the ratio of ascorbic acid and / or its salt to component (A) is preferably 0.1 parts by mass or more, more preferably 0.5 parts by mass or more, even more preferably 1 part by mass or more, even more preferably 3 parts by mass or more, particularly preferably 5 parts by mass or more, and most preferably 7 parts by mass or more, per 1 part by mass of component (A). It may also be 0.05 parts by mass or more, or 0.01 parts by mass or more. It may also be 10 parts by mass or more, 20 parts by mass or more, 50 parts by mass or more, or 100 parts by mass or more. Furthermore, the ratio of ascorbic acid and / or its salt to 1 part by mass of component (A) is preferably 300 parts by mass or less, more preferably 150 parts by mass or less, even more preferably 100 parts by mass or less, even more preferably 70 parts by mass or less, particularly preferably 50 parts by mass or less, and most preferably 30 parts by mass or less. It may also be 400 parts by mass or less, or 500 parts by mass or less. It could be 20 parts by mass or less, 10 parts by mass or less, 5 parts by mass or less, 1 part by mass or less, etc.

[0086] Examples of peptides include soy-derived peptides, milk-derived peptides, fish-derived peptides, and egg-derived peptides, with soy-derived peptides being preferred.

[0087] The compositions of the present invention may contain additives as long as they do not impair the effects of the present invention. Specific examples of such additives include sugar alcohols, oils and fats, binders, flavorings, excipients, disintegrants, lubricants, colorants, flavoring agents, odor masking agents, sugars, polyhydric alcohols, high-intensity sweeteners, emulsifiers, thickeners, acidulants, fruit juices, and the like.

[0088] Examples of sugar alcohols include lactose, maltose, fructose, sorbitol, maltitol, mannitol, xylitol, or trehalose.

[0089] Examples of oils and fats include vegetable oils such as castor oil, cottonseed oil, soybean oil, camellia oil, olive oil, sesame oil, pea oil, corn oil, coconut oil, rapeseed oil, wheat germ oil, safflower oil, sunflower oil, safflower oil, perilla oil, hydrogenated oil, and cocoa butter; animal oils such as pork fat, beef fat, milk fat, and liver oil, which are stabilized by hydrogenating coconut oil; mineral oils such as silicone oil; and functional oils such as medium-chain triglycerides and long-chain triglycerides.

[0090] Examples of functional oils include short-chain fatty acids with 2 to 4 carbon atoms, medium-chain fatty acids with 5 to 12 carbon atoms, or compounds in which fatty acids with longer chains than 12 carbon atoms are ester-bonded to mono-decaglycerol. Examples of short-chain fatty acids include butyric acid, while examples of medium-chain fatty acids include valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, and lauric acid. Examples of long-chain fatty acids include myristic acid, pentadecyl acid, palmitic acid, palmitoleic acid, margaric acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidic acid, arachidonic acid, behenic acid, lignoceric acid, nervonic acid, cerotic acid, montanic acid, and melissic acid.

[0091] Examples of binders include cellulose derivatives such as methylcellulose, ethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, acrylic acid polymers, gelatin, gum arabic, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, and propylene glycol alginate.

[0092] While not limited to these, preferred additives include sugar alcohols, fats and oils, binders, and / or fragrances.

[0093] [Manufacturing method] The method for producing the oral composition of the present invention is not particularly limited, and known methods can be used. Specifically, one method is to stir each component while heating it as necessary to dissolve or disperse it, mix it, stir it while cooling it, and then let it stand at room temperature, but the method is not particularly limited thereto.

[0094] [Formulation] The composition of the present invention may be an oral composition. The formulation form of the oral composition is not particularly limited and may be a solid preparation such as a tablet (including orally disintegrating tablets, chewable tablets, lozenges, etc.), granules, powder, soft capsule, hard capsule, lozenge, jelly, or liquid preparation. Examples include suspensions, emulsions, syrups, etc. Among these, solid formulations are preferred from the viewpoint of ease of handling and further enhancing the effects of the present invention, and tablets or granules are more preferred.

[0095] [Uses and dosage, etc.] The compositions of the present invention can be used, for example, as ingredients in pharmaceuticals, quasi-drugs, cosmetics, and food and beverage products (beverages, food). Furthermore, the oral compositions according to this embodiment can be used, for example, in pharmaceutical formulations, quasi-drug formulations, as well as in foods such as Foods for Specified Health Uses, Foods with Nutritional Function Claims, Foods for the Elderly, Foods for Special Dietary Uses, Foods with Function Claims, Health Supplements, and Food Formulations (e.g., confectionery tablets). The compositions of the present invention may be useful in maintaining skin moisture, reducing redness, increasing collagen score, improving skin firmness, moisture, smoothness, or wrinkles.

[0096] When the composition of the present invention is used as food or beverage, the food may contain component (A), component (B), and other components as needed, in addition to general food products. Examples of such food or beverages include solid foods such as cookies, biscuits, snacks, jelly, gummies, chocolate, gum, candy, and cheese; and liquid foods such as nutritional drinks, juices, tea beverages, coffee beverages, and dairy beverages.

[0097] In the present invention, the amount of the composition of the present invention incorporated into pharmaceutical preparations, quasi-drug preparations, foods for specified health uses, foods with nutritional function claims, foods for the elderly, foods for special dietary uses, foods with functional claims, health supplements, and food preparations (e.g., confectionery tablets) is not particularly limited. However, the daily dose of the composition of the present invention for adults can be, for example, 0.1 g or more, preferably 0.2 g or more, more preferably 0.3 g or more, and most preferably 0.55 g or more. Alternatively, it can be used in amounts of, for example, 8 g or less, preferably 7 g or less, more preferably 6 g or less, and most preferably 5 g or less.

[0098] The total daily intake of ascorbic acid in the formulation of the present invention may vary depending on the individual's condition (weight, age, sex, etc.) and the formulation form of the composition, but for example, it is preferably 10 mg or more, more preferably 100 mg or more, even more preferably 200 mg or more, and even more preferably 300 mg or more. It may also be 3000 mg or less, preferably 2500 mg or less, and more preferably 2000 mg or less. It may also be 400 mg or more, 500 mg or more, 600 mg or more, 1000 mg or more, 1500 mg or more, or 2000 mg or more.

[0099] The compositions of the present invention may be stored and / or sold in known containers (packaging materials) in dosages sufficient for one week or more, ten days or more, fourteen days or more, twenty days or more, or thirty days or more.

[0100] [Containers containing polyolefin-based resins] The composition of the present invention can be contained in a container containing a polyolefin-containing resin. The container preferably has a polyolefin-containing layer on the surface in contact with the composition. Here, the polyolefin is preferably polyethylene (PE) (including high-density polyethylene (HDPE), low-density polyethylene (LDPE), ultra-low-density polyethylene, linear low-density polyethylene (LLDPE), ultra-high molecular weight polyethylene, etc.), polypropylene (PP) (including homopolymers, random copolymers, block copolymers, etc.), and ethylene-propylene copolymer, cyclic olefin copolymer, polymethylpentene, and polybutene-1,1,2-polybutadiene, with polyethylene resin or polypropylene resin being more preferred. Of these, it is particularly preferable that the resin contains at least polyethylene. The polyolefin-containing layer may consist solely of polyolefin, but it is sufficient that it contains polyolefin, and the proportion is not limited. It may also contain aluminum. For example, packaging materials having a layer with an aluminum content of 3% or more by mass, or 5% or more by mass, can be used. The aluminum layer is preferably 1 μm or more, 3 μm or more, or 5 μm or more, and preferably 20 μm or less, 15 μm or less, or 10 μm or less. Here, the packaging material may be multilayered or single-layered, and the form is not limited as long as it contains polyolefin. It may also contain polyester. Of the layers, the layer containing polyolefin or the layer made of polyolefin that is in contact with the composition is preferably 5 μm or more, 10 μm or more, 20 μm or more, 30 μm or more, or 40 μm or more, and preferably 100 μm or less, 80 μm or less, 60 μm or less, 50 μm or less, or 40 μm or less.

[0101] [Composition for reducing adhesion to resin layers containing polyolefins] In one embodiment of the present invention, it is also possible to provide a composition for reducing adhesion to a polyolefin-containing resin layer, comprising (A) liposomes; and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. By coexisting (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen with (A) liposomes, the adhesion to the polyolefin-containing layer can be reduced. The content of each component and other conditions are as described in [Composition containing liposomes].

[0102] [Containers containing polyester-based resins] The composition of the present invention can be contained in a container containing a polyester-containing resin. The container preferably has a polyester-containing layer on the surface in contact with the composition. Here, the polyester is preferably polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polyethylene naphthalate (PEN), polybutylene naphthalate (PBN), polyethylene isophthalate (PEIT), or polycaprolactone (PCL), and more preferably a resin containing at least polyethylene terephthalate. Aluminum may also be included. For example, packaging materials having layers with an aluminum content of 3% or more by mass, or 5% or more by mass, can be used. The aluminum layer is preferably 1 μm or more, 3 μm or more, or 5 μm or more, and preferably 20 μm or less, 15 μm or less, or 10 μm or less. Here, the packaging material may be multilayer or single-layer, and the form is not limited as long as polyester is included. Polyolefin may also be included.

[0103] [Composition for reducing adhesion to resin layers containing polyester] In one embodiment of the present invention, it is also possible to provide a composition for reducing adhesion to a polyester-containing resin layer, comprising (A) liposomes; and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. By coexisting (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen with (A) liposomes, the adhesion to the polyester-containing layer can be reduced. The content of each component and other conditions are as described in [Composition containing liposomes].

[0104] [Container containing a layer with HPMC] The composition of the present invention can be contained in a container having a layer containing HPMC on the surface in contact with the composition. The layer containing HPMC may consist solely of HPMC, but it is sufficient that it contains HPMC, and the proportion is not limited. For example, a hard capsule can be used that has a layer on the surface in contact with the composition containing 70% or more by mass of HPMC, or 85% or more by mass of HPMC. Here, the container, such as a capsule, may be multilayered or single-layered, and the form is not limited as long as HPMC is contained on the surface in contact with the composition.

[0105] [Composition for reducing adhesion to layers containing HPMC] In one embodiment of the present invention, it is also possible to provide a composition for reducing adhesion to a layer containing HPMC, comprising (A) liposomes; and (B) at least one selected from the group consisting of plants and / or their extracts, hyaluronic acid, ceramide, and collagen. By coexisting (A) liposomes with (B) at least one selected from the group consisting of plants and / or their extracts, hyaluronic acid, ceramide, and collagen, the adhesion to the layer containing HPMC can be reduced. Less adhesion of HPMC to the hard capsule material reduces the likelihood of weight errors during filling and makes filling easier, thus offering significant manufacturing advantages. The content of each component and other conditions are as described in [Composition containing liposomes].

[0106] [Container containing a gelatin-based layer] The composition of the present invention can be contained in a container having a gelatin-containing layer on the surface in contact with the composition. The gelatin-containing layer may consist solely of gelatin, but it is sufficient that it contains gelatin, and the proportion is not limited. For example, a hard capsule can be used that has a layer with a gelatin content of 70% or more and 85% or more on the surface in contact with the composition. Here, the container, such as a capsule, may be multilayered or single-layered, and the form is not limited as long as gelatin is contained on the surface in contact with the composition.

[0107] [Composition for reducing adhesion to gelatin-containing layers] In one embodiment of the present invention, it is also possible to provide a composition for reducing adhesion to a gelatin-containing layer, comprising (A) liposomes; and (B) at least one selected from the group consisting of plant extracts, hyaluronic acid, ceramide, and collagen. By coexisting (A) liposomes with (B) at least one selected from the group consisting of plant extracts, ceramide, and hyaluronic acid, the adhesion to the gelatin-containing layer can be reduced. The content of each component and other conditions are as described in [Composition containing liposomes].

[0108] [Composition for reducing adhesion] In one embodiment of the present invention, it is also possible to provide a composition for reducing adhesion, which contains (A) liposomes; and (B) at least one selected from the group consisting of plant extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. That is, by reducing adhesion to packaging materials and containers, it is possible to make a composition that is easy to take or has high filling efficiency. The content of each component and other conditions are in accordance with the contents described in [Compositions Containing Liposomes].

[0109] [Composition for preventing discoloration] In one embodiment of the present invention, it is also possible to provide a discoloration-inhibiting composition containing (A) liposomes; and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. By providing a composition containing A) liposomes and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen, a discoloration-inhibiting effect can be achieved. The content of each component and other conditions are in accordance with the contents described in [Compositions Containing Liposomes].

[0110] [Composition for improving skin moisture content] In one embodiment of the present invention, it is also possible to provide a composition for improving skin moisture content, comprising (A) liposomes; and (B) at least one selected from the group consisting of plant and / or its extract, oil-coated ascorbic acid and / or its salt, hyaluronic acid, ceramide, and collagen. By applying a composition containing A) liposomes and (B) at least one selected from the group consisting of plant and / or its extract, oil-coated ascorbic acid and / or its salt, hyaluronic acid, ceramide, and collagen, the moisture content of the skin can be improved. The content of each component and other conditions are as follows: The contents described in [Compositions Containing Liposomes] shall be as specified.

[0111] [Composition for improving collagen score] In one embodiment of the present invention, it is also possible to provide a composition for improving the collagen score, which contains (A) liposomes; and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. By applying a composition containing A) liposomes and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen, the collagen score of the skin can be improved. The collagen score is a value that represents the collagen density in the dermis, and a higher value indicates a higher collagen density. The content of each component and other conditions are as described in [Compositions Containing Liposomes].

[0112] [Composition for reducing skin redness] In one embodiment of the present invention, it is also possible to provide a composition for reducing skin redness, comprising (A) liposomes; and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. By applying a composition comprising A) liposomes and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen, skin redness can be reduced. Skin redness may also be a reflection of the suppression of skin inflammation. The content of each component and other conditions are in accordance with the description in [Compositions Containing Liposomes].

[0113] [Composition for improving capillary blood vessels] In one embodiment of the present invention, it is also possible to provide a composition for improving capillaries, which contains (A) liposomes; and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. By applying a composition containing A) liposomes and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen, it is possible to reduce the leakage of water from the blood due to the decrease or decline in the function of normal capillaries. By improving capillaries, it is possible to prevent blood leakage from weakened blood vessels and improve blood flow. The content of each component and other conditions are in accordance with the contents described in [Composition containing liposomes].

[0114] [Composition for improving skin smoothness] In one embodiment of the present invention, it is also possible to provide a composition for improving skin smoothness that contains (A) liposomes; and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. By applying a composition containing A) liposomes and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen, skin smoothness can be improved. Skin smoothness refers to a state of skin that does not have a rough feeling. The content of each component and other conditions are in accordance with the contents described in [Composition containing liposomes].

[0115] [Wrinkle-improving composition] In one embodiment of the present invention, it is also possible to provide a wrinkle-improving composition containing (A) liposomes; and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. Skin wrinkles can be improved by applying a composition containing A) liposomes and (B) at least one selected from the group consisting of plants and / or their extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen. Skin wrinkles include wrinkles around the mouth and eyes. The content of each component and other conditions are in accordance with the contents described in [Compositions Containing Liposomes]. [Examples]

[0116] Next, the present invention will be specifically described with reference to examples and test cases, but the present invention is not limited to the following examples and test cases. Unless otherwise specified, the units of each component amount in the table are mass (g). The following reagents were used. Liposome VC: Ascorbic acid-containing liposomes (Test examples 1 and 2: Product name: Vitamin C Zeal: α-Link Co., Ltd., Test example 3: Product name: Liposomal PureWay-C Fine Powder: Maypro Industries Co., Ltd.) Sustained-release VC: (Product name: VC-90R: NOF Corporation) Long pepper extract: (Product name: Tie2 Long Pepper Extract Powder MF: Maruzen Pharmaceutical Co., Ltd.) Job's Tears Extract: (Product Name: Job's Tears Extract Powder MF: Maruzen Pharmaceutical Co., Ltd.) Collagen: Collagen peptide (Product name: ROUSSELOT PEPTAN F5000HD: Roussellot Co., Ltd.) Centella Asiatica Extract: (Product Name: Centevita (Centella Asiatica Extract): Unikiss Co., Ltd.) Hyaluronic acid: (Product name: Low molecular weight hyaluronic acid: Chori Co., Ltd.) Ceramide: (Product name: Konjac Ceramide (powder type): Daicel Corporation) Glutathione: (Product name: Hi-thion Extract YH-D20: Mitsubishi Corporation Life Sciences Co., Ltd.) NMN: (Product name: Fermented NMN: Nippon Bulk Pharmaceuticals) Water chestnut extract: (Product name: Water chestnut extract: Hayashikane Sangyo) Placenta: (Product name: P-Placenta Extract: Nippon Ham) Ginger extract: (Product name: GINGER EXTRACT 15%: Bio Actives Japan) Pomegranate extract: (Pomegranate extract powder 10: Ikeda Sugar Refining Co., Ltd.) Aluminum pouch: (Product name: AL-G (PET12 / SPE15 / AL7 / SPE15 / PE40): Manufactured by Nippon Co., Ltd.) HPMC: (Product name: QUALI-VN: Qualicaps Corporation)

[0117] [Test Example 1. Adhesion Confirmation Test 1] Compositions for the Examples and Comparative Examples having the compositions shown in Tables 1 and 2 below were prepared. One g of each composition was placed on a board with an aluminum pouch attached. A beaker containing 200 mL of water was placed on top as a weight for 3 seconds, then removed. After ensuring consistent adhesion conditions for the composition to the board, the composition was slid down a distance of 10 cm. The slope of the slope was 60 degrees. The amount of composition remaining attached to the aluminum pouch was measured. Table 1 shows the retention rate, the rate of change, and the rate of suppression of change at each slope angle. The surface of the aluminum pouch was coated with a resin containing polyester.

[0118] Here, the remaining rate refers to the percentage of powder that remains attached to the plate to which the aluminum pouch is attached, and was calculated using the following formula: Remaining rate = Amount of powder remaining after tilting ÷ Amount of powder initially placed on the plate Percentage change in remaining material (%) = 100 × [Remaining material rate of the target example / Remaining material rate of comparative example 1] Change suppression rate (%) = 100 × [1 - (Remaining change rate of Example 2 / Remaining change rate of Comparative Example 2)]

[0119] [Test Example 2. Discoloration Inhibition Confirmation Test] After preparing each of the example and comparative examples compositions having the compositions shown in Table 1, 2 g was weighed out and sealed in a glass bottle. The color difference of the powder was then measured using a spectrophotometer (CM-5, Konica Minolta, Inc.). The bottle was then sealed and left to stand at 60°C for 18 days. After 18 days, the color difference of the powder was measured again using the same method, and the difference in ΔE*ab values ​​before and after storage was calculated to evaluate the discoloration.

[0120] Table 1 shows the component content and the suppression rate of color difference change for each composition. The color difference change rate was determined for Comparative Example 2 based on Comparative Example 1, and the change suppression rate was calculated using the following formula based on Comparative Example 2. Color difference change rate (%) = 100 × [Color difference change rate of the target example / Color difference change rate of comparative example 1-1] Color difference suppression rate (%) = 100 × [1 - (Color difference change in Example / Color difference change in Comparative Examples 1-2)]

[0121] [Table 1] [Table 2]

[0122] The results shown in Table 1 first indicate that compositions containing liposome VC tend to adhere to aluminum pouches. In the example compositions, adhesion to aluminum pouches was suppressed, demonstrating improved ease of removal from the packaging material.

[0123] Next, it was shown that compositions containing liposome VC were prone to discoloration during storage, while the compositions in the examples demonstrated that discoloration was suppressed.

[0124] Adhesion to aluminum pouches occurs with liposomal vitamin C and ascorbic acid across a wide range of concentrations. Even without the excipients sodium ascorbate and lactose, adhesion issues persist, which are resolved by the inclusion of component B.

[0125] [Test Example 3. Adhesion Confirmation Test 2] Compositions for the Examples and Comparative Examples having the compositions shown in Tables 3 and 4 below were prepared. 1 g of each composition was placed on a board with an HPMC sheet attached, and a beaker containing 200 mL of water was placed on top as a weight for 3 seconds, then slid down a distance of 10 cm. The slope of the slide at that time was 60 degrees. The amount of composition remaining attached to the HPMC sheet was measured. The retention rate, rate of change, and rate of suppression of change for each composition are shown in Tables 3 and 4.

[0126] In Table 3, the remaining rate refers to the remaining amount of powder that adheres to the board to which the HPMC sheet is attached, and was calculated using the following formula: Remaining rate = Amount of powder remaining after tilting ÷ Amount of powder initially placed on the board Percentage change of remaining powder (%) = 100 × [Remaining rate of the target example / Remaining rate of Comparative Example 3-1] Suppression rate of change (%) = 100 × [1 - (Percentage change of the example / Percentage change of Comparative Example 3-2)]

[0127] [Table 3] In Table 4, the remaining rate refers to the remaining rate of powder that adheres to the board to which the HPMC sheet was attached, and was calculated using the following formula. Percentage change in remaining material (%) = 100 × [Remaining material rate of the target example / Remaining material rate of comparative example 4-1] Change suppression rate (%) = 100 × [1 - (Remaining change rate of Example 4-2 / ​​Remaining change rate of Comparative Example 4-2)] [Table 4]

[0128] Adhesion to HPMC sheets occurs with a wide range of concentrations of liposomal vitamin C and ascorbic acid. Even without the excipients sodium ascorbate and lactose, adhesion issues persisted, which were resolved by the inclusion of component B. Similarly, adhesion issues also occurred when using gelatin sheets instead of HPMC, and these were resolved by the inclusion of component B.

[0129] [Test Example 4. Discoloration Inhibition Confirmation Test] After preparing each of the example and comparative examples compositions having the compositions shown in Table 5, 2 g was weighed out and sealed in a 2 cm × 9.5 cm aluminum pouch. The color difference of the powder was then measured using a spectrophotometer (CM-5, Konica Minolta, Inc.). The pouch was then sealed again and left to stand at 60°C for 18 days. After 18 days, the color difference of the powder was measured again using the same method, and the difference in the value of ΔE*abΔ before and after storage was calculated to evaluate the discoloration.

[0130] Table 5 shows the component content and the color difference change rate (percentage when the color difference change in Comparative Example 5-1 is set to 100%) for each composition. [Table 5]

[0131] [Test Example 5. Adhesion Confirmation Test 3] Compositions for the Examples and Comparative Examples having the compositions shown in Table 6 below were prepared. In the same manner as in Test Example 1, 1 g of each composition was placed on a board with an aluminum pouch attached. A beaker containing 200 mL of water was placed on top as a weight for 3 seconds, then removed. After ensuring that the adhesion conditions of the composition to the board were constant, the board was slid down a distance of 10 cm. The slope of the slope at that time was 60 degrees. The amount of composition remaining attached to the aluminum pouch was measured. Table 1 shows the retention rate, the rate of change, and the rate of suppression of change at each slope angle. The surface of the aluminum pouch was coated with a polyethylene-containing resin.

[0132] Here, the remaining rate refers to the percentage of powder that remains attached to the plate to which the aluminum pouch is attached, and was calculated using the following formula. Survival rate = Amount of powder remaining after tilting ÷ Amount of powder initially placed on the plate Percentage change in remaining material (%) = 100 × [Remaining material rate of the target example / Remaining material rate of comparative example 6-1] Change suppression rate (%) = 100 × [1 - (Remaining change rate of Example 6-2 / Remaining change rate of Comparative Example 6-2)]

[0133] [Table 6]

[0134] Adhesion occurs with a wide range of concentrations of liposome VC and ascorbic acid. Furthermore, even without lactose, which is used as an excipient, adhesion issues persisted, and these were resolved by incorporating component B. Similarly, adhesion problems occurred not only with the aluminum pouches used in the examples, but also with aluminum pouches where the innermost layer is PET, or when using HPMC or gelatin sheets, and these issues were resolved by incorporating component B.

[0135] Compared to the composition of Comparative Example 5-1 sealed in an aluminum pouch, the compositions of Examples 5-1 to 5-6, also sealed in aluminum pouches, showed suppressed discoloration despite having a higher ascorbic acid content, due to the inclusion of component B. Furthermore, even without the excipients sodium ascorbate and lactose, discoloration issues arose, which were resolved by the inclusion of component B.

[0136] [Test Example 6. Discoloration Inhibition Confirmation Test 2] After preparing each of the compositions for the examples and comparative examples having the compositions shown in Table 7, 2 g was weighed out as in Test Example 4, sealed in a 2 cm × 9.5 cm aluminum pouch, and the color difference of the powder was measured using a spectrophotometer (CM-5, Konica Minolta, Inc.). The pouch was then sealed again and left to stand at 60°C for 18 days. After 18 days, the color difference of the powder was measured in the same manner, and the difference in the value of ΔE*abΔ before and after storage was calculated to evaluate the discoloration.

[0137] Table 7 shows the component content and the color difference change rate (percentage when the color difference change in Comparative Example 7-1 is set to 100%) for each composition.

[0138] [Table 7]

[0139] [Example 5: Human Clinical Trials] A composition (granules) of the example having the composition shown in Table 8 below was prepared. This composition was administered orally once a day at breakfast, dissolved in drinking water or the like, for 4 weeks in a single-group open-label study (5000 mg / day). Skin moisture content, collagen score, skin color, and capillary count were examined before and after oral administration.

[0140] [Table 8]

[0141] The measurements were performed on 15 women aged 30 to under 60. Skin moisture content was measured using a Corneometer CM825 (registered trademark) manufactured by Courage-Khazaka, collagen score was measured using an ultrasound dermal imaging device (DermaLab (registered trademark) manufactured by Coetex Technoloqy), Hb-Index and color difference were measured using a Konica Minolta spectrophotometer CM-2600d manufactured by Konica Minolta, and capillary count was measured using a capillary scope "Ketsukan Bijin" manufactured by Atto Co., Ltd. Skin moisture content, collagen score, and color difference were measured at the same location on the left cheek. Capillary count was measured slightly below the boundary between the nail and skin on the left ring finger. For skin moisture content and color difference, the average of three measurements for all participants was taken; for collagen score, the average of two measurements for all participants was taken; and for capillary count, the result of one measurement was taken.

[0142] As a result, both skin moisture content and collagen score were found to have significantly increased four weeks after ingestion compared to before ingestion. Using the pre-ingestion level as 100%, the levels were 113.3% and 111.5%, respectively.

[0143] The color difference (a value) and Hb-Index significantly decreased 4 weeks after ingestion compared to before ingestion. In other words, skin redness was reduced. With the pre-ingestion level set at 100%, the values ​​were 94.7% and 92.4%, respectively.

[0144] The number of capillaries significantly increased four weeks after ingestion compared to before ingestion. Before ingestion, there were 5.1 capillaries per unit area of ​​a given visual field, compared to 5.7 capillaries per unit area of ​​the same visual field after ingestion.

[0145] [Test Example 8. Confirmation Test using VAS] Similarly, 13 subjects were orally administered the composition of the example having the composition shown in Table 8 for four consecutive weeks (5000 mg / day), and skin changes were examined at two and four weeks after administration compared to the start of administration. The test was evaluated using the Visual Analog Scale (VAS) method. That is, for each test item, subjects were asked to indicate the result of the evaluation at one point on a 10 cm straight line, with the distance (mm) from the 0 mm point being measured to obtain a sensory score. Skin moisture: 0 mm for "not at all," 100 mm for "very much." Skin smoothness: 0 mm for "very rough," 100 mm for "very smooth." Skin firmness: 0 mm for "not at all," 100 mm for "very much." Fine lines around the eyes and mouth: 0 mm for "not at all noticeable," 100 mm for "very noticeable." The results are shown in Table 9. (VAS method)

[0146] [Table 9] The results showed that when the composition of the example was administered, after two weeks, improved skin moisture, smoothness, and firmness, as well as improvement in fine wrinkles around the eyes and mouth, were felt. Furthermore, after four weeks from administration, the effects were felt to an even greater degree.

Claims

1. (A) Liposomes; and, (B) A composition containing at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or salt thereof, ginger extract, pomegranate extract, plant and / or extract thereof, oil-coated ascorbic acid and / or salt thereof, hyaluronic acid, ceramide, and collagen.

2. The composition according to claim 1, wherein part or all of the surface that comes into contact with the composition is housed in a container containing a resin that contains polyolefin.

3. The composition according to claim 1, wherein part or all of the surface that comes into contact with the composition is housed in a container containing HPMC and / or gelatin.

4. (A) Liposomes; and, (B) A composition for reducing adhesion, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

5. The composition according to claim 4, wherein the decrease in adhesion is a decrease in adhesion to a layer containing polyolefin, HPMC, or gelatin.

6. (A) Liposomes; and, (B) A discoloration-inhibiting composition containing at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

7. (A) Liposomes; and, (B) A composition for improving skin moisture content, comprising: glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or salt thereof, ginger extract, pomegranate extract, plant and / or extract thereof, oil-coated ascorbic acid and / or salt thereof, hyaluronic acid, ceramide, and collagen;

8. (A) Liposomes; and, (B) A composition for improving collagen score, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salt, ginger extract, pomegranate extract, plant and / or its extract, oil-coated ascorbic acid and / or its salt, hyaluronic acid, ceramide, and collagen.

9. (A) Liposomes; and, (B) A composition for reducing redness of the skin, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

10. (A) Liposomes; and, (B) A composition for improving capillaries, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salt, ginger extract, pomegranate extract, plant and / or its extract, oil-coated ascorbic acid and / or its salt, hyaluronic acid, ceramide, and collagen.

11. (A) Liposomes; and, (B) A composition for improving skin smoothness, comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

12. (A) Liposomes; and, (B) A wrinkle-improving composition comprising at least one selected from the group consisting of glutathione, nicotinamide mononucleotide, water chestnut extract, placenta, pyrroloquinoline quinone and / or its salts, ginger extract, pomegranate extract, plant and / or its extracts, oil-coated ascorbic acid and / or its salts, hyaluronic acid, ceramide, and collagen.

13. Furthermore, the composition according to any one of claims 1 to 12, further comprising ascorbic acid and / or a salt of ascorbic acid.

14. The composition according to any one of claims 1 to 12, wherein the plant or extract thereof is one or more selected from the group consisting of Centella asiatica, long pepper, and Job's tears, or an extract thereof.

15. The composition according to any one of claims 1 to 12, wherein the component (A) is a liposome containing ascorbic acid and / or a salt thereof.

Images